Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases

October 25, 2022

Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases

October 19, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 17, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 20, 2022

Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022

September 12, 2022

Gritstone to Participate in Two Upcoming Investor Conferences

September 1, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2022

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

August 15, 2022

Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

August 10, 2022

Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update

August 4, 2022

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

© 2023 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top